LINC01327

Across TCGA pan-cancer cohorts, LINC01327 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated LINC01327 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher LINC01327 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01327 expression acts as an unfavorable survival marker, although some lineages such as PAAD and LUAD show a favorable association.

MESO, KIRC, and BLCA are the cancer types where LINC01327 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	IV	0.036	0.602	<.001	126	view →
KIRC	DFS	Tertile	All	0.148	0.634	<.001	108	view →
BLCA	DFS	Tertile	All	0.148	0.629	<.001	45	view →
LAML	DFS	Tertile	All	0.243	0.516	.005	18	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	18	view →
PAAD	DFS	Tertile	All	1.000	0.235	.028	18	view →
UCEC	OS	Tertile	All	0.875	0.929	.014	12	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.234	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

LINC01327–MESO (OS)

Open the MESO breakdown →